On Friday, Terns Pharmaceuticals Inc (NASDAQ: TERN) opened lower -3.88% from the last session, before settling in for the closing price of $4.64. Price fluctuations for TERN have ranged from $4.16 to $11.40 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -25.00%. Company’s average yearly earnings per share was noted 6.27% at the time writing. With a float of $62.32 million, this company’s outstanding shares have now reached $84.92 million.
Let’s determine the extent of company efficiency that accounts for 66 employees. In terms of profitability, gross margin is 47.35%, operating margin of -7562.78%, and the pretax margin is -6641.75%.
Terns Pharmaceuticals Inc (TERN) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Terns Pharmaceuticals Inc is 26.63%, while institutional ownership is 71.68%. The most recent insider transaction that took place on Jan 02 ’25, was worth 25,607. In this transaction Chief Medical Officer of this company sold 4,481 shares at a rate of $5.71, taking the stock ownership to the 54,269 shares. Before that another transaction happened on Jan 06 ’25, when Company’s Chief Financial Officer sold 9,059 for $5.80, making the entire transaction worth $52,500. This insider now owns 74,752 shares in total.
Terns Pharmaceuticals Inc (TERN) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.32 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 6.27% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -4.53% during the next five years compared to -12.40% drop over the previous five years of trading.
Terns Pharmaceuticals Inc (NASDAQ: TERN) Trading Performance Indicators
Check out the current performance indicators for Terns Pharmaceuticals Inc (TERN). In the past quarter, the stock posted a quick ratio of 32.99.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.18, a number that is poised to hit -0.30 in the next quarter and is forecasted to reach -1.32 in one year’s time.
Technical Analysis of Terns Pharmaceuticals Inc (TERN)
Looking closely at Terns Pharmaceuticals Inc (NASDAQ: TERN), its last 5-days average volume was 2.58 million, which is a jump from its year-to-date volume of 1.9 million. As of the previous 9 days, the stock’s Stochastic %D was 40.89%. Additionally, its Average True Range was 0.34.
During the past 100 days, Terns Pharmaceuticals Inc’s (TERN) raw stochastic average was set at 4.08%, which indicates a significant decrease from 38.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 66.59% in the past 14 days, which was lower than the 78.43% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.63, while its 200-day Moving Average is $6.88. However, in the short run, Terns Pharmaceuticals Inc’s stock first resistance to watch stands at $4.66. Second resistance stands at $4.87. The third major resistance level sits at $4.99. If the price goes on to break the first support level at $4.34, it is likely to go to the next support level at $4.22. Now, if the price goes above the second support level, the third support stands at $4.01.
Terns Pharmaceuticals Inc (NASDAQ: TERN) Key Stats
There are currently 84,939K shares outstanding in the company with a market cap of 378.83 million. Presently, the company’s annual sales total 0 K according to its annual income of -90,210 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -21,950 K.
